The Pharma Polymers Business Line, part of Evonik Industries AG, Essen, will implement price increases for its methyl methacrylate-based polymers for pharmaceutical applications by up to 8 % for their global EUDRAGIT® business, effective beginning of Q1/2008.
Pharma Polymers has optimized its supply chain and improved efficiency in its processes. Despite these initiatives, the increased costs of operations, transportation and raw materials could not be compensated.
Pharma Polymers is continuing to invest proactively in the reliability of supply and in its global technical capabilities. These investments will further increase the security of supply and support the success of their pharmaceutical customers in creating competitive advantages in their markets.
Evonik Industries is the creative industrial group from Germany which operates in three business areas: Chemicals, Energy and Real Estate. Evonik is a global leader in specialty chemicals, an expert in power generation from hard coal and renewable energies, and one of the largest private residential real estate companies in Germany. Our strengths are creativity, specialization, continuous self-renewal, and reliability. Evonik is active in over 100 countries around the world. In its fiscal year 2006 more than 43,000 employees generated sales of about Euro 14.8 billion and an operating profit (EBIT) of over Euro 1.2 billion.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.